title: Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
abstract: OBJECTIVE
  To examine whether proton-pump inhibitor (PPI) therapy influences the incidence and progression of dysplasia in patients with Barrett's oesophagus.
  
  
  METHODS
  Review of prospective data on patients undergoing surveillance with regular endoscopy and biopsy at a private endoscopy centre in Canberra, ACT, between 1981 and 2001.
  
  
  METHODS
  350 patients diagnosed with Barrett's oesophagus.
  
  
  METHODS
  PPI therapy was progressively introduced into clinical practice from late 1989. Once begun, PPI therapy was ongoing, with no attempt to reduce the dose.
  
  
  METHODS
  Relationship between development of dysplasia or adenocarcinoma and delay between diagnosis with Barrett's oesophagus and starting PPI therapy was determined by Cox regression analyses, stratified by year of enrollment. Age, sex, presence of macroscopic markers (severe oesophagitis, nodularity, Barrett's ulcer, stricture) and use of aspirin or non-steroidal anti-inflammatory drugs were considered as confounding factors in the regression analyses.
  
  
  RESULTS
  The 350 patients had 1422 surveillance endoscopies, with a median follow-up of 4.7 years. Patients who delayed using a PPI for 2 years or more after diagnosis with Barrett's oesophagus had 5.6 times (95% CI, 2.0-15.7) the risk of developing low-grade dysplasia at any given time as those who used a PPI in the first year. Similar results were found for the risk of developing high-grade dysplasia or adenocarcinoma (hazard ratio, 20.9; 95% CI, 2.8-158).
  
  
  CONCLUSIONS
  Use of ongoing PPI therapy appeared beneficial in the prevention of dysplasia and adenocarcinoma in patients with Barrett's oesophagus. We suggest that all patients with this condition, even those with no oesophagitis or symptoms, should be encouraged to continue long term PPI therapy.
authors.affiliation: Mugga Wara and Brindabella Endoscopy Centres, 7/5 Dann Close, Garran, ACT 2605, Australia. l.hillman@gastrotract.com.au
authors.forename: Lybus C
authors.initials: LC
authors.lastname: Hillman
authors.forename: Louise
authors.initials: L
authors.lastname: Chiragakis
authors.forename: Bruce
authors.initials: B
authors.lastname: Shadbolt
authors.forename: Graham L
authors.initials: GL
authors.lastname: Kaye
authors.forename: Anthony C
authors.initials: AC
authors.lastname: Clarke
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D018450:Disease Progression; D016099:Endoscopy, Gastrointestinal; D004938:Esophageal Neoplasms / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D054328:Proton Pump Inhibitors; D017494:Proton Pumps